Sintalica’s approach to psychedelic drug discovery aims to enhance the molecule’s strong anti-inflammatory properties while removing hallucinogenic effects. Their research and drug development program focus on neurodegenerative disorders, such as SCI-Induced Chronic Neuropathic Pain, Fibromyalgia, and Inflammation.
Sintalica’s scientific team comprises leading scientists in chemistry, pharmacology, biotechnology, and neurodegenerative diseases, with exclusive partnerships with leading Italian research institutes, including the University of Messina and the University of Niccolò Cusano of Rome.
“We are confident our proprietary molecules and unique formulations will lead to breakthrough treatments for neuroinflammatory diseases,” said Bruce Linton, Chairman, and Co-Founder of Sintalica.
Prof. Salvatore Cuzzocrea, Rector of the University of Messina, remarked, “The successful cultivation of mushrooms combined with the synthesis of unique non-hallucinogenic molecules is a big achievement for Sintalica, the University of Messina, and Italy’s drug development industry. We are now looking forward to starting our drug development program’s next phase.”
Sintalica Bioscience Corp. is a Canadian drug discovery company that operates through its Italian subsidiary. They have filed four provisional patents for proprietary psychedelic molecules with improved stability and safety profiles, reduced hallucinogenic effects, and enhanced bioavailability.